PURPOSE: To compare the preferences of women and health professionals for key attributes of noninvasive prenatal diagnosis for Down syndrome relative to current invasive tests. METHODS: A questionnaire incorporating a discrete choice experiment was used to obtain participants' stated preference for diagnostic tests that varied according to four attributes: accuracy, time of test, risk of miscarriage, and provision of information about Down syndrome only or Down syndrome and other conditions. Women and health professionals were recruited from five maternity services in England and a patient support group. RESULTS: Questionnaires from 335 women and 181 health professionals were analyzed. Safe tests, conducted early in pregnancy, with high accuracy and information about Down syndrome and other conditions were preferred. The key attribute affecting women's preferences for testing was no risk of miscarriage, whereas for health professionals it was accuracy. CONCLUSIONS: Policies for implementing noninvasive prenatal diagnosis must consider the differences between women's and health professionals' preferences to ensure the needs of all stakeholders are met. Women's strong preference for tests with no risk of miscarriage demonstrates that consideration for safety of the fetus is paramount in decision making. Effective pretest counseling is therefore essential to ensure women understand the possible implications of results.
PURPOSE: To compare the preferences of women and health professionals for key attributes of noninvasive prenatal diagnosis for Down syndrome relative to current invasive tests. METHODS: A questionnaire incorporating a discrete choice experiment was used to obtain participants' stated preference for diagnostic tests that varied according to four attributes: accuracy, time of test, risk of miscarriage, and provision of information about Down syndrome only or Down syndrome and other conditions. Women and health professionals were recruited from five maternity services in England and a patient support group. RESULTS: Questionnaires from 335 women and 181 health professionals were analyzed. Safe tests, conducted early in pregnancy, with high accuracy and information about Down syndrome and other conditions were preferred. The key attribute affecting women's preferences for testing was no risk of miscarriage, whereas for health professionals it was accuracy. CONCLUSIONS: Policies for implementing noninvasive prenatal diagnosis must consider the differences between women's and health professionals' preferences to ensure the needs of all stakeholders are met. Women's strong preference for tests with no risk of miscarriage demonstrates that consideration for safety of the fetus is paramount in decision making. Effective pretest counseling is therefore essential to ensure women understand the possible implications of results.
Authors: Edward J D Webb; David Meads; Ieva Eskytė; Helen L Ford; Hilary L Bekker; Jeremy Chataway; George Pepper; Joachim Marti; Yasmina Okan; Sue H Pavitt; Klaus Schmierer; Ana Manzano Journal: Patient Date: 2020-10 Impact factor: 3.883
Authors: M A Allyse; L C Sayres; M Havard; J S King; H T Greely; L Hudgins; J Taylor; M E Norton; M K Cho; D Magnus; K E Ormond Journal: Prenat Diagn Date: 2013-05-21 Impact factor: 3.050
Authors: Rachèl V van Schendel; Johanna H Kleinveld; Wybo J Dondorp; Eva Pajkrt; Danielle R M Timmermans; Kim C A Holtkamp; Margreet Karsten; Anne L Vlietstra; Augusta M A Lachmeijer; Lidewij Henneman Journal: Eur J Hum Genet Date: 2014-03-19 Impact factor: 4.246
Authors: Melissa Hill; Jo-Ann Johnson; Sylvie Langlois; Hyun Lee; Stephanie Winsor; Brigid Dineley; Marisa Horniachek; Faustina Lalatta; Luisa Ronzoni; Angela N Barrett; Henna V Advani; Mahesh Choolani; Ron Rabinowitz; Eva Pajkrt; Rachèl V van Schendel; Lidewij Henneman; Wieke Rommers; Caterina M Bilardo; Paula Rendeiro; Maria João Ribeiro; José Rocha; Ida Charlotte Bay Lund; Olav B Petersen; Naja Becher; Ida Vogel; Vigdis Stefánsdottir; Sigrun Ingvarsdottir; Helga Gottfredsdottir; Stephen Morris; Lyn S Chitty Journal: Eur J Hum Genet Date: 2015-11-18 Impact factor: 4.246